市場調査レポート

商品コード

1466028

キャッスルマン病治療市場：疾患タイプ、適応症、治療法、用途別-世界予測2024-2030年

Castleman Disease Treatment Market by Disease Type, Indication, Treatment, Application - Global Forecast 2024-2030

出版日: 2024年04月17日 | 発行: 360iResearch

| ページ情報: 英文 196 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF, Excel & Online Access - 1 Year (Single User License)

USD 4,749 743,930円

レポートPDF及びExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Up to 5 User License)

USD 5,749 900,580円

レポートPDF及びExcelを5名まで共有ご利用頂けるライセンスです。ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Site License)

USD 6,749 1,057,230円

レポートPDF及びExcelを同一事業所（所在地）内のすべての方でご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Enterprise User License)

USD 8,749 1,370,530円

レポートPDF及びExcelを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.65円

ご注意事項 :

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

キャッスルマン病治療市場規模は、2023年に2億9,433万米ドルと推定され、2024年には3億3,415万米ドルに達し、CAGR 13.62%で2030年には7億1,987万米ドルに達すると予測されています。

キャッスルマン病治療では、キャッスルマン病と呼ばれる稀な病気を管理するための専門的な医療処置が含まれます。この病気は、体内のリンパ節で細胞が過剰に増殖することを特徴とし、発熱や疲労から異常な体重減少まで様々な症状を引き起こします。近年、キャッスルマン病を含む希少疾患の有病率が増加しており、治療の選択肢を増やす必要があります。キャッスルマン病に対する理解は年々進んでおり、標的療法の開発につながっています。現在進行中の研究は、バイオマーカーの同定、基礎となる病態生理学の理解、新規治療法の発見に重点を置いています。キャッスルマン病に対するいくつかの治療法は希少疾病用医薬品の指定を受けており、製薬会社にとって希少疾病の治療法開発のインセンティブとなっています。しかし、薬剤開発のコストが高いこと、治療の選択肢が限られていること、規制遵守が厳しいことなどが、治療の拡大を妨げています。ヘルスケア専門家、研究者、支援団体は、キャッスルマン病の診断、管理、治療を改善するために世界規模で協力しています。

主な市場の統計
基準年[2023］	2億9,433万米ドル
予測年［2024]	3億3,415万米ドル
予測年 [2030]	7億1,987万米ドル
CAGR（%）	13.62%

疾患の種類多中心性キャッスルマン病は全身臓器不全の可能性があるため、治療戦略の迅速な展開が必要

多中心性キャッスルマン病（MCD）とは、患者の体の複数の部位にリンパ節腫大を引き起こす病態を指します。多中心性キャッスルマン病には、多発性神経炎、臓器腫大、内分泌障害、M蛋白、皮膚変化（POEMS）関連MCD、ヒトヘルペスウイルス-8（HHV-8）関連MCD、特発性MCDの3つの分類があります。多中心性キャッスルマン病の治療には、一般的に細胞の過剰増殖を抑制するための薬物療法やその他の治療法が用いられます。具体的な治療法は、病気の程度や、患者がヒト免疫不全ウイルス感染症（HIV）、ヒトヘルペスウイルス-8（HHV-8）感染症、またはその両方に感染しているかどうかによっても異なります。一中心性キャッスルマン病（UCD）とは、通常胸部または腹部の1つのリンパ節が侵される疾患です。一中心性キャッスルマン病は、外科的に病変のあるリンパ節を切除することで治療することができます。

適応血管腫様リンパ節症例に対するキャッスルマン病治療の選択肢の増加

血管腫様リンパ節過形成は、長引く発熱、貧血、体重減少、脾腫、高ガンマグロブリン血症を伴う。血管腫様リンパ球過誤腫または偽リンパ腫は、胸部で最も多く報告されており、通常、リンパ腫様組織の胸腺腫瘍と間違われます。まれな症状であり、免疫調節療法がしばしば用いられます。キャッスルマン腫瘍は、胸腺腫に類似した珍しい縦隔リンパ節過形成です。特徴的な組織学的特徴には、小結節におけるリンパ球の玉ねぎ皮状配列および顕著な毛細血管増殖を伴う異常な血管系が含まれます。巨大良性リンパ腫は、大腸に発生する最も一般的な非上皮性良性腫瘍です。通常、直腸に直径数mmから3～4cmの赤紫色または灰色の単一の丸みを帯びたポリープとして観察されます。巨大リンパ節過形成は原因不明の非腫瘍性リンパ増殖性疾患で、通常胸部に発現します。この疾患の形態学的認識は、様々な組織学的特徴の組み合わせに基づいています。リンパ節血管筋腫性過誤腫（AMH-LN）とは、平滑筋、血管、膠質間質、および脂肪細胞の異常な良性増殖を指します。

治療法化学療法の進歩により、キャッスルマン病治療オプションの採用が拡大しています。

抗ウイルス薬は有害なウイルスを標的として使用されます。抗ウイルス薬は病気の症状を和らげるために使用されます。化学療法とは、患者の体内で急速に増殖するがん細胞を死滅させるために薬物や化学療法を利用することを指します。エトポシドの連日経口投与59やエトポシドやビンブラスチンの間欠投与などの低用量単剤化学療法がMCDに用いられています。コルチコステロイドは強力な抗炎症薬であり、疾患の症状を緩和することができます。副腎皮質ステロイドの全身投与は、症状の緩和をもたらすが、腫瘍の縮小を予測することはできないです。免疫療法は、身体の自然な防御機能を利用して病気と闘います。モノクローナル抗体とは、実験室で作られた、1つの病原性抗原のみに結合するタンパク質のことです。HHV-8関連MCDでは、リツキシマブによる治療が非常に有効です。HIV感染者の一部には、リツキシマブとともに抗レトロウイルス療法（ART）を併用する必要があります。放射線療法とは、放射線を照射してがん細胞を死滅させ、腫瘍を縮小させるがん治療のことです。単中心性キャッスルマン病では、放射線療法は奏効率が高く、有効な治療選択肢です。

申請最適な患者ケアを提供するため外来手術センターが好まれる

外来手術センター（ASC）とは、診断や予防処置を含む外科的治療を即日提供することを目的とした近代的な医療施設を指します。これらのセンターは、その医療効率の高さと治療予約にかかる待ち時間の短縮により、キャッスルマン病の治療に徐々に普及してきました。病院部門は、複雑な疾病管理の性質に付随するケアの強度のため、引き続きキャッスルマン病治療に大きく貢献しています。

地域別インサイト

南北アメリカ、特に米国とカナダは、キャッスルマン病を含む希少疾患の診断と治療のためのインフラが比較的確立されています。キャッスルマン病に特化した専門の医療センターや専門家が存在し、患者支援団体や研究機関が診断や治療に対する認識や進歩に貢献しています。アジアでは、キャッスルマン病治療へのアクセスは他の地域と比較して限られているが、ヘルスケア開発への政府の投資により、希少疾患に対するより重点的なアプローチが大幅に進められています。この地域の主要都市では高度な診断・治療オプションが提供されており、中国、日本、インドでは小規模な学術機関が研究開発活動に多額の投資を行っています。欧州では、政府がヘルスケアと研究活動における利害関係者の協力を推進しており、キャッスルマン病の治療に役立っています。欧州医薬品庁は、この地域のキャッスルマン病患者への治療の提供とアクセスを向上させるため、改良された医薬品の審査と承認に取り組んでいます。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはキャッスルマン病治療市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、キャッスルマン病治療市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.キャッスルマン病治療市場の市場規模および予測は？

2.キャッスルマン病治療市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.キャッスルマン病治療市場の技術動向と規制枠組みは？

4.キャッスルマン病治療市場における主要ベンダーの市場シェアは？

5.キャッスルマン病治療市場への参入に適した形態や戦略的手段は？

市場力学
- 促進要因
  - キャッスルマン病の有病率と効果的な疾患管理の必要性
  - キャッスルマン病治療薬の希少疾病用医薬品指定および承認の提供
  - キャッスルマン治療に対する患者支援団体と啓発プログラムの台頭
- 抑制要因
  - キャッスルマン病の治療薬開発の複雑さ
- 機会
  - 新しいキャッスルマン病治療の開発の継続的な進歩
  - キャッスルマン病治療の個別化医療の新たなトレンド
- 課題
  - 標準化された治療プロトコルの欠如
市場セグメンテーション分析
- 疾患タイプ：全身臓器不全の可能性があるため、多中心性キャッスルマン病に対する治療戦略の迅速な展開の必要性
- 適応症：血管腫性リンパ腫症例へのキャッスルマン病治療選択肢の採用増加
- 治療：化学療法の進歩によりキャッスルマン病治療オプションの採用が拡大
- 用途：最適な患者ケアの提供による外来手術センターの優先
市場ディスラプション分析
ポーターのファイブフォース分析
バリューチェーンとクリティカルパス分析
価格分析
技術分析
特許分析
貿易分析
規制枠組みの分析

第6章キャッスルマン病治療市場：疾患タイプ別

多中心性キャッスルマン病
単中心性キャッスルマン病

第7章キャッスルマン病治療市場適応症別

血管濾胞リンパ節増殖症
血管腫性リンパ管
キャッスルマン腫瘍
巨大良性リンパ腫
巨大リンパ節増殖症
リンパ管過誤腫

第8章キャッスルマン病治療市場治療別

抗ウイルス薬
化学療法
コルチコステロイド
免疫療法
モノクローナル抗体
放射線治療

第9章キャッスルマン病治療市場：用途別

外来手術センター
病院

第10章南北アメリカのキャッスルマン病治療市場

アルゼンチン
ブラジル
カナダ
メキシコ
米国

第11章アジア太平洋地域のキャッスルマン病治療市場

オーストラリア
中国
インド
インドネシア
日本
マレーシア
フィリピン
シンガポール
韓国
台湾
タイ
ベトナム

第12章欧州・中東・アフリカのキャッスルマン病治療市場

デンマーク
エジプト
フィンランド
フランス
ドイツ
イスラエル
イタリア
オランダ
ナイジェリア
ノルウェー
ポーランド
カタール
ロシア
サウジアラビア
南アフリカ
スペイン
スウェーデン
スイス
トルコ
アラブ首長国連邦
英国

第13章競合情勢

市場シェア分析2023
FPNVポジショニングマトリックス、2023
競合シナリオ分析
- FDAがトシリズマブのバイオシミラーを承認 Tofidence
- 中外製薬、日本で「アクテムラ」のがん治療に伴うサイトカイン放出症候群に対する効能追加承認を取得
- Medableは、Every Cureと提携して希少疾患の治療法の発見を加速します
戦略分析と提言

第14章競合ポートフォリオ

主要企業プロファイル
主要製品ポートフォリオ

図表

LIST OF FIGURES

FIGURE 1. CASTLEMAN DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CASTLEMAN DISEASE TREATMENT MARKET DYNAMICS
FIGURE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 12. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 14. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. CASTLEMAN DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. CASTLEMAN DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

TABLE 1. CASTLEMAN DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MULTICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MULTICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY UNICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY UNICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOMATOUS LYMPHOID, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOMATOUS LYMPHOID, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CASTLEMAN TUMOR, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CASTLEMAN TUMOR, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT BENIGN LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT BENIGN LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT LYMPH NODE HYPERPLASIA, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT LYMPH NODE HYPERPLASIA, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HAMARTOMA OF THE LYPHATICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HAMARTOMA OF THE LYPHATICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 48. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 49. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 50. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 51. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 52. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 53. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 54. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 55. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 56. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 57. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 58. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 59. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 60. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 61. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 62. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 63. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 64. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 65. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 66. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 67. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 68. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 69. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 70. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 71. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 72. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 73. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 74. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 75. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 76. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 77. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 78. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 79. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 80. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 81. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 82. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 83. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 84. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 85. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 86. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 87. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 88. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 89. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 90. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 91. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 92. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 93. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 94. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 95. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 96. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 97. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 98. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 100. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 102. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 104. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 106. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 108. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 109. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 110. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 111. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 112. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 113. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 114. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 115. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 116. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 117. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 118. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 119. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 120. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 121. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 122. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 123. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 124. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 125. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 126. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 127. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 128. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 129. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 130. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 131. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 132. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 133. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 134. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 135. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 136. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 137. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 138. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 139. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 140. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 141. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 142. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 143. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 144. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 145. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 146. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 147. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 148. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 149. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 150. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 151. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 152. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 153. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 154. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 155. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 156. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 157. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 158. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 159. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 160. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 161. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 162. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 163. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 164. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 165. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 166. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 167. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 168. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 169. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 170. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 171. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 172. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 173. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 174. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 175. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 176. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 177. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 178. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 179. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 180. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 181. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 182. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 183. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 184. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 185. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 186. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 187. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 188. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 189. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 190. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 191. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 192. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 193. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 194. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 195. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 196. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 197. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 198. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 199. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 200. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 201. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 202. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 203. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 204. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 215. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 216. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 217. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 218. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 219. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 220. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 221. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 222. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 223. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 224. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 225. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 226. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 227. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 228. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 229. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 230. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 231. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 232. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 233. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 234. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 235. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 236. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 237. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 238. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 239. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 240. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 241. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 242. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 243. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 244. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 245. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 246. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 247. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 248. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 249. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 250. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 251. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 252. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 253. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 254. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 255. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 256. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 257. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 258. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 259. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 260. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 261. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 262. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 263. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 264. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 265. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 266. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 267. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 268. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 269. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 270. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 271. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 272. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 273. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 274. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 275. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 276. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 277. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 278. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 279. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 280. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 281. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 282. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 283. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 284. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 285. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 286. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 287. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 288. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 289. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 290. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 291. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 292. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 293. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 294. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 295. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 296. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 297. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 298. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 299. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 300. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 301. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 302. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 303. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 304. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 305. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 306. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 307. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 308. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 309. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 310. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 311. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 312. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 313. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 314. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 315. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 316. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 317. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 318. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 320. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 322. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDI

Product Code: MRR-4312A385A340

[196 Pages Report] The Castleman Disease Treatment Market size was estimated at USD 294.33 million in 2023 and expected to reach USD 334.15 million in 2024, at a CAGR 13.62% to reach USD 719.87 million by 2030.

Castleman disease treatment involves a specialized healthcare procedure to manage a rare illness called Castleman disease, which is characterized by the overgrowth of cells in the body's lymph nodes, causing a variety of symptoms from fever and fatigue to abnormal weight loss. Recent years have observed an increased prevalence of rare diseases, including Castleman disease, necessitating enhanced treatment options. The understanding of Castleman disease has advanced over the years, leading to the development of targeted therapies. Ongoing research focuses on identifying biomarkers, understanding the underlying pathophysiology, and discovering novel treatment options. Some treatments for Castleman disease have received orphan drug designation, which provides incentives for pharmaceutical companies to develop therapies for rare diseases. However, the high cost of drug development, limited treatment options, and strict regulatory compliance impede the expansion of treatment. Healthcare professionals, researchers, and advocacy groups are collaborating on a global scale to improve the diagnosis, management, and treatment of Castleman disease.

KEY MARKET STATISTICS
Base Year [2023]	USD 294.33 million
Estimated Year [2024]	USD 334.15 million
Forecast Year [2030]	USD 719.87 million
CAGR (%)	13.62%

Disease type: Need for rapid deployment of treatment strategies for multicentric Castleman's disease due to the chances of systemic organ failure

Multicentric Castleman's disease (MCD) refers to the disease condition that causes lymph node enlargement in multiple regions of the patient's body. There are three categories of MCD-Polyneuropathy, organomegaly, endocrinopathy, M proteins, and skin changes (POEMS)-associated MCD, human herpesvirus-8 (HHV-8)-associated MCD, and idiopathic MCD. Treatment for multicentric Castleman disease generally involves medicines and other therapies to control cell overgrowth. Specific treatment may also depend on the extent of the disease and whether the patient has human immunodeficiency virus infection (HIV), human herpesvirus-8 (HHV-8) infection, or both. Unicentric Castleman's disease (UCD) refers to a disorder that affects a single lymph node in the patient's body, usually in the chest or abdomen. Unicentric Castleman disease can be treated by surgically removing the diseased lymph node.

Indication: Rising adoption of Castlemann's disease treatment options for tackling angiomatous lymphoid cases

Angiofollicular lymph node hyperplasia is associated with prolonged fever, anemia, weight loss, splenomegaly, and hypergammaglobulinemia. Angiomatous lymphoid hamartomas or pseudolymphomas have been reported most commonly within the chest and are usually mistaken for thymic tumors of lymphomatous tissue. It is a rare manifestation where immunomodulatory treatment is often utilized. Castleman tumor is an unusual mediastinal lymph node hyperplasia that resembles thymoma. The characteristic histologic characteristics include an onion skin arrangement of the lymphocytes in nodules and an unusual vasculature with marked capillary proliferation. Giant benign lymphoma is the most common non-epithelial benign tumor occurring in the large intestine. It is usually observed in the rectum as a single reddish-purple or grey, rounded polyp varying in diameter from a few millimeters to 3-4 centimeters. Giant lymph node hyperplasia is a nonneoplastic lymphoproliferative disorder of unknown etiology that is usually observed in the chest. The morphological recognition of this disease is based on a combination of various histological features. Angiomyomatous hamartoma of lymph nodes (AMH-LN) refers to an unusual benign proliferation of smooth muscle, blood vessels, collagenous stroma, and adipocytes.

Treatment: Advancements in chemotherapy treatments leading to expanding adoption of Castleman disease treatment options

Antiviral medications are used to target harmful viruses. The antiviral drugs are used to ease disease symptoms. Chemotherapy refers to the practice of utilizing a drug or chemical treatment to kill fast-growing cancer cells in a patient's body. Low-dose single-agent chemotherapy treatment options, such as daily oral etoposide59 or intermittent etoposide or vinblastine, have been utilized for MCD. Corticosteroids are powerful anti-inflammatory drugs that can mitigate disease symptoms. Systemic corticosteroids can provide symptomatic relief but do not predictably reduce tumor size. Immunotherapy takes advantage of the body's natural defenses to fight the disease. Monoclonal antibodies refer to proteins made in a laboratory that bind to one pathogenic antigen only. In HHV-8-associated MCD, treatment with rituximab is highly effective. For some patients with HIV infection, antiretroviral therapy (ART) should be included with the rituximab. Radiation therapy refers to a cancer treatment that uses bursts of radiation to target and kill cancer cells and shrink tumors. In unicentric Castleman disease, radiotherapy radiation therapy is a viable treatment option because of its high response rates.

Application: Preference for ambulatory surgical centers due to provision of optimum patient care

Ambulatory surgical centers (ASCs) refer to modern medical facilities that aim to provide same-day surgical care, including diagnostic and preventive procedures. These centers have gradually become popular for the treatment of Castleman disease due to their perceived medical efficiency and the reduced waiting times involved in scheduling a treatment. The hospital segment continues to remain a significant contributor to Castleman disease treatment owing to the intensity of care that comes with the complex nature of disease management.

Regional Insights

The Americas, particularly the U.S. and Canada, has a relatively well-established infrastructure for rare disease diagnosis and treatment, including Castleman disease. There are specialized medical centers and experts focused on the condition, and patient advocacy groups and research institutes have contributed to the awareness and advancements in diagnosis and treatment. In Asia, access to castle treatment is limited when compared to the other regions; however, the government investment in healthcare development has significantly strived toward a more focused approach to rare diseases. Major cities in the region offer advanced diagnostic and treatment options, and small-scale academic institutes in China, Japan, and India are investing heavily in R&D activities. In Europe, the government promotes stakeholder cooperation in healthcare and research activities, benefiting the treatment of Castleman disease. The European Medicines Agency has been working on reviewing improved medications and approving them to elevate the provision and access to Castleman treatment to patients in the region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Castleman Disease Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Castleman Disease Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Castleman Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Amgen Inc., Artiva Biotherapeutics, Inc., Bayer AG, Bio-Rad Laboratories, Inc., Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Celltrion Healthcare Co.,Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals S.A., Johnson & Johnson Services, Inc., LGM Pharma, Merck & Co., Inc., Novartis AG, Octapharma AG, Pfizer, Inc., Recordati Group Company, Recordati S.p.A., Sanofi S.A., Sartorius AG, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Castleman Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Disease Type
- Multicentric Castleman's Disease
- Unicentric Castleman's Disease

Indication
- Angiofollicular Lymph Node Hyperplasia
- Angiomatous Lymphoid
- Castleman Tumor
- Giant Benign Lymphoma
- Giant Lymph Node Hyperplasia
- Hamartoma of the Lyphatics

Treatment
- Antiviral Drugs
- Chemotherapy
- Corticosteroids
- Immunotherapy
- Monoclonal Antibodies
- Radiation Therapy

Application
- Ambulatory Surgical Centers
- Hospitals

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Castleman Disease Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Castleman Disease Treatment Market?

3. What are the technology trends and regulatory frameworks in the Castleman Disease Treatment Market?

4. What is the market share of the leading vendors in the Castleman Disease Treatment Market?

5. Which modes and strategic moves are suitable for entering the Castleman Disease Treatment Market?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of Castleman disease and the need for effective disease management
  - 5.1.1.2. Provision of orphan drug designation and approvals for Castleman disease treatments
  - 5.1.1.3. Rise of patient advocacy groups and awareness programs for Castleman treatment
- 5.1.2. Restraints
  - 5.1.2.1. Complexities in the drug development for Castleman disease
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing advancements in the development of new Castleman disease treatment
  - 5.1.3.2. Emerging trend of personalized medicine for Castleman disease treatment
- 5.1.4. Challenges
  - 5.1.4.1. Lack fo standardized treatment protocols
5.2. Market Segmentation Analysis
- 5.2.1. Disease type: Need for rapid deployment of treatment strategies for multicentric Castleman's disease due to the chances of systemic organ failure
- 5.2.2. Indication: Rising adoption of Castlemann's disease treatment options for tackling angiomatous lymphoid cases
- 5.2.3. Treatment: Advancements in chemotherapy treatments leading to expanding adoption of Castleman disease treatment options
- 5.2.4. Application: Preference for ambulatory surgical centers due to provision of optimum patient care
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Castleman Disease Treatment Market, by Disease Type

6.1. Introduction
6.2. Multicentric Castleman's Disease
6.3. Unicentric Castleman's Disease

7. Castleman Disease Treatment Market, by Indication

7.1. Introduction
7.2. Angiofollicular Lymph Node Hyperplasia
7.3. Angiomatous Lymphoid
7.4. Castleman Tumor
7.5. Giant Benign Lymphoma
7.6. Giant Lymph Node Hyperplasia
7.7. Hamartoma of the Lyphatics

8. Castleman Disease Treatment Market, by Treatment

8.1. Introduction
8.2. Antiviral Drugs
8.3. Chemotherapy
8.4. Corticosteroids
8.5. Immunotherapy
8.6. Monoclonal Antibodies
8.7. Radiation Therapy

9. Castleman Disease Treatment Market, by Application

9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Hospitals

10. Americas Castleman Disease Treatment Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Castleman Disease Treatment Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Castleman Disease Treatment Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. FDA Approves Tocilizumab Biosimilar Tofidence
- 13.3.2. Chugai Obtains Approval for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Therapy in Japan
- 13.3.3. Medable Partners with Every Cure to Accelerate Discovery of Treatments for Rare Diseases
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio

キャッスルマン病治療市場：疾患タイプ、適応症、治療法、用途別-世界予測2024-2030年

Castleman Disease Treatment Market by Disease Type, Indication, Treatment, Application - Global Forecast 2024-2030

本レポートは、以下の側面に関する貴重な洞察を提供しています：

本レポートは、以下のような主要な質問に対応しています：

目次

第1章序文

第2章調査手法

第3章エグゼクティブサマリー

第4章市場の概要

第5章市場洞察

第6章キャッスルマン病治療市場：疾患タイプ別

第7章キャッスルマン病治療市場適応症別

第8章キャッスルマン病治療市場治療別

第9章キャッスルマン病治療市場：用途別

第10章南北アメリカのキャッスルマン病治療市場

第11章アジア太平洋地域のキャッスルマン病治療市場

第12章欧州・中東・アフリカのキャッスルマン病治療市場

第13章競合情勢

第14章競合ポートフォリオ

LIST OF FIGURES

LIST OF TABLES

This research report categorizes the Castleman Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Castleman Disease Treatment Market, by Disease Type

7. Castleman Disease Treatment Market, by Indication

8. Castleman Disease Treatment Market, by Treatment

9. Castleman Disease Treatment Market, by Application

10. Americas Castleman Disease Treatment Market

11. Asia-Pacific Castleman Disease Treatment Market

12. Europe, Middle East & Africa Castleman Disease Treatment Market

13. Competitive Landscape

14. Competitive Portfolio

キャッスルマン病治療市場：疾患タイプ、適応症、治療法、用途別-世界予測2024-2030年

Castleman Disease Treatment Market by Disease Type, Indication, Treatment, Application - Global Forecast 2024-2030

本レポートは、以下の側面に関する貴重な洞察を提供しています：

本レポートは、以下のような主要な質問に対応しています：

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

第6章 キャッスルマン病治療市場：疾患タイプ別

第7章 キャッスルマン病治療市場適応症別

第8章 キャッスルマン病治療市場治療別

第9章 キャッスルマン病治療市場：用途別

第10章 南北アメリカのキャッスルマン病治療市場

第11章 アジア太平洋地域のキャッスルマン病治療市場

第12章 欧州・中東・アフリカのキャッスルマン病治療市場

第13章 競合情勢

第14章 競合ポートフォリオ

LIST OF FIGURES

LIST OF TABLES

This research report categorizes the Castleman Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Castleman Disease Treatment Market, by Disease Type

7. Castleman Disease Treatment Market, by Indication

8. Castleman Disease Treatment Market, by Treatment

9. Castleman Disease Treatment Market, by Application

10. Americas Castleman Disease Treatment Market

11. Asia-Pacific Castleman Disease Treatment Market

12. Europe, Middle East & Africa Castleman Disease Treatment Market

13. Competitive Landscape

14. Competitive Portfolio

第1章序文

第2章調査手法

第3章エグゼクティブサマリー

第4章市場の概要

第5章市場洞察

第6章キャッスルマン病治療市場：疾患タイプ別

第7章キャッスルマン病治療市場適応症別

第8章キャッスルマン病治療市場治療別

第9章キャッスルマン病治療市場：用途別

第10章南北アメリカのキャッスルマン病治療市場

第11章アジア太平洋地域のキャッスルマン病治療市場

第12章欧州・中東・アフリカのキャッスルマン病治療市場

第13章競合情勢

第14章競合ポートフォリオ